Literature DB >> 9771669

Quantification of early damage in latissimus dorsi muscle grafts.

A T Tang1, P S Hasleton, H Reid, T L Hooper.   

Abstract

Acute damage in the latissimus dorsi muscle may account for variable clinical results following dynamic cardiomyoplasty and an ischemic cause has been suggested. Using established techniques, we set out to demonstrate and to quantify the acute muscle damage in a rodent model. The left latissimus dorsi muscle of 5 Sprague-Dawley rats was mobilized on its thoracodorsal vascular pedicle, thus interrupting the regional blood supply to its distal part. The undisturbed contralateral muscle served as a matched control. After 24 hours, the muscle was excised and divided into proximal, middle, and distal thirds. Damage was graded histologically and quantified by nitroblue tetrazolium macrohistochemistry. Both methods of assessment correlated well (r=-0.936; P < 0.001) and demonstrated significant damage, principally in the middle and the distal regions of the ischemic muscles. Therefore, the rodent model appears to be useful for investigating the pathogenesis and prevention of acute ischemic damage in the latissimus dorsi graft under conditions resembling the clinical scenario.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9771669     DOI: 10.1002/(sici)1097-4598(199811)21:11<1451::aid-mus13>3.0.co;2-3

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability.

Authors:  P W Hamer; J M McGeachie; M J Davies; M D Grounds
Journal:  J Anat       Date:  2002-01       Impact factor: 2.610

2.  Surgical implantation of a bioengineered internal anal sphincter.

Authors:  Mohamed Hashish; Shreya Raghavan; Sita Somara; Robert R Gilmont; Eiichi Miyasaka; Khalil N Bitar; Daniel H Teitelbaum
Journal:  J Pediatr Surg       Date:  2010-01       Impact factor: 2.545

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.